Manulife Receives TSX Approval for Previously Announced 42M Share Buyback Program

summarizeSummary

Manulife Financial received TSX approval for its previously announced Normal Course Issuer Bid, authorizing the repurchase of up to 42 million common shares, or approximately 2.5% of its outstanding stock.

check_boxKey Events

• TSX Approval for Share Buyback

  Manulife received approval from the Toronto Stock Exchange for its Normal Course Issuer Bid (NCIB), following prior approval from the Office of the Superintendent of Financial Institutions.

• Significant Share Repurchase Program

  The NCIB authorizes the company to repurchase up to 42 million common shares, representing approximately 2.5% of its issued and outstanding shares.

• Program Execution Timeline

  Purchases under the NCIB may commence on February 24, 2026, and continue until February 23, 2027, or until the maximum shares are purchased.

• Capital Management Strategy

  The buyback is part of Manulife's capital management strategy, designed to maintain healthy regulatory capital ratios and generate shareholder value.

auto_awesomeAnalysis

This filing confirms the Toronto Stock Exchange's approval for Manulife's Normal Course Issuer Bid (NCIB), allowing the company to proceed with repurchasing up to 42 million common shares. This program, representing approximately 2.5% of outstanding shares, was previously announced on February 12, 2026. The approval enables Manulife to execute its capital management strategy, which aims to enhance shareholder value by reducing the number of outstanding shares. Purchases are set to begin on February 24, 2026, and will continue for up to one year.